1. MAIA announces private placement of 1,233,488 shares at $1.224 each. 2. Proceeds will fund Phase II trial for THIO and working capital. 3. Warrants offered with shares at $1.36 exercise price, valid for three years. 4. Private placement expected to close around December 18, 2025. 5. Forward-looking statements indicate potential uncertainties impacting future performance.
FAQ
Why Bullish?
The private placement indicates investor confidence and a funding boost. Historical instances show similar placements often lead to increased stock prices due to enhanced funding for growth.
How important is it?
The funding directly supports clinical development, crucial for market perception and future growth. Investors generally favor companies that show proactive funding strategies, enhancing MAIA's attractiveness.
Why Short Term?
Immediate effects are expected as the private placement funds expedited trials. Previous similar placements have shown quick impacts on stock valuation.
MAIA Biotechnology Secures $1.51 Million in Private Placement
CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) has announced a significant step in its financial strategy by entering into definitive agreements for the purchase and sale of 1,233,488 shares of common stock. Priced at $1.224 per share, this private placement aims to enhance the company's capital to support its innovative cancer therapies.
Details of the Private Placement
The private placement will involve accredited investors and a company director, with each share coupled with a warrant to purchase one additional share at an exercise price of $1.36. This price aligns with the "Minimum Price" defined under NYSE American Rule 713, ensuring compliance with established regulations.
Key features of the offering include:
- Issuance of 1,233,488 shares of common stock
- Warrants with an exercise price of $1.36 per share
- Warrants are exercisable six months post-issuance
- Three-year term for warrants from the date of issuance
This private placement is projected to close around December 18, 2025, pending customary closing conditions.
Use of Proceeds from the Offering
MAIA intends to utilize the net proceeds, estimated at nearly $1.51 million before offering expenses, to finance Step 1 of Part C of the Phase II clinical trial for its investigational immunotherapy, THIO-101. These proceeds will also contribute to general working capital, facilitating the company’s ongoing commitment to developing innovative cancer treatments.
Regulatory Considerations
It is crucial to note that the securities offered in this private placement have not been registered under the Securities Act of 1933 or any applicable state securities laws. Consequently, both the warrants and the underlying shares of common stock can only be offered or sold in the U.S. with a valid registration statement or an applicable exemption.
This announcement should not be interpreted as an offer to sell or a solicitation to purchase these securities in any jurisdiction where such an offer would be illegal prior to proper registration or qualification under the securities laws.
About MAIA Biotechnology
MAIA Biotechnology is at the forefront of the immuno-oncology field, concentrating on the development and commercialization of potential first-in-class therapies. Their primary focus is on ateganosine (THIO), a groundbreaking telomere targeting agent currently in clinical development for treating non-small cell lung cancer (NSCLC) in patients with telomerase-positive cancer cells. For more information about MAIA and its initiatives, visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that this announcement includes forward-looking statements that are subject to risks and uncertainties. These statements relate to future events and the company's expectations regarding financial outcomes and clinical developments, which may differ materially from actual results.
Statements regarding the completion of the private placement, the initiation, timing, and results of clinical studies, and the market acceptance of MAIA's product candidates all represent potential outcomes, but they carry inherent uncertainties. The company undertakes no obligation to update any forward-looking statements unless required by law.
Contact Information
For investor inquiries, please contact MAIA Biotechnology:
- Phone: +1 (872) 270-3518
- Email: ir@maiabiotech.com